Structure Therapeutics Inc.

Departure of Chief Technology Officer

On November 6, 2026, Yingli Ma, Ph.D. resigned from her position as Chief Technology Officer and entered into a resignation and release agreement (the “Separation Agreement”) with Shanghai ShouTi Biotechnology Co., Ltd. (“Shanghai ShouTi”), a wholly-owned subsidiary of the Company. Dr. Ma will be departing from her position as Chief Technology Officer effective as of November 13, 2026 (the “Separation Date”). The Separation Agreement, among other things, provides for Dr. Ma to continue to receive the salary and benefits through her Separation Date in accordance with the employment contract by and between Shanghai ShouTi and Dr. Ma, dated May 11, 2024 (the “Ma Employment Agreement”), addresses treatment of Dr. Ma’s equity awards and continuing obligations under the Ma Employment Agreement, effective from the Separation Date.

The foregoing description of the Separation Agreement is not complete and is subject to and qualified in its entirety by reference to the complete text of the Separation Agreement, a copy of which the Company intends to file with the Securities and Exchange Commission as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2026.

Trading Arrangements

During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K).